Financing channel feed – Endpoints News

Financing channel feed

As investors soured on his bets, records show Woodford paid himself handsome dividends

6 years ago

Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal

6 years ago

The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer

6 years ago

Offering much needed relief for Woodford-associated funds, sequencing unicorn Oxford Nanopore raises $105.9M in new cash

6 years ago

Banking on Shanghai's biotech boom, this Eli Lilly-backed player grabs $100M to push next-gen I/O therapies

6 years ago

Cirius withdraws $86M IPO as vaunted 'Year of NASH' draws to brutal close

6 years ago

Kinnate jumps onto the biotech stage with $74.5M and a fledgling cancer drug pipeline

6 years ago

Forma Therapeutics bounces back from Celgene fallout with $100 million Series D

6 years ago

Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand

6 years ago

Canaan backs Pathios' search for small molecule drugs that hit 'orphan' GCPR

6 years ago

No pain, no gain: Company-building French VC scores €250M for life sciences fund

6 years ago

What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that

6 years ago

Alphamab Oncology rounds out HKEX's second biotech IPO year with $230M raise and high local interest

6 years ago

After several high profile startup launches, omnivorous Omega Funds closes $438M fund to pursue more deals

6 years ago

Perceptive teams up with Chris Garabedian to open up a new, $210M biotech fund focused on A rounds

6 years ago

Jasper Therapeutics launches out of Stanford with new approach to stem cell treatment

6 years ago

Black Diamond raises another $85M to bring new oncogene approach into clinic

6 years ago

Antibody strategy to augment versatile immune cells sparks investment in French biotech

6 years ago

On the heels of $225M royalty deal, Kodiak shoots for $250M raise to fund pivotal programs of its Eylea slayer

6 years ago

Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey

6 years ago

With momentum from FDA OK, SK Biopharma to breath new life into Korean biotech with $850M IPO — report

6 years ago

Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test

6 years ago

Cancer Research UK spinoff raises $41M+ in Series B injection

6 years ago

MPM and Longwood-backed Werewolf Therapeutics grabs $56 million to take tumors by night

6 years ago

First page Previous page 105 106 107108109 110 111 Next page Last page